SEC Form 4 · accession 0001179110-18-003493
ACCELERON PHARMA INC · XLRN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Habib J Dable
Officer — CEO and President · Director
Period of report
Mar 1, 2018
Accepted (ET)
Mar 5, 2018 · 5:13 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001280600
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Mar 1, 2018 | A | 18,100 | $0.00 | A | 80,900 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Option to Purchase Common StockF1 | $40.61 | Mar 1, 2018 | A | 108,800 | A | — | Mar 1, 2028 | Common Stock | 108,800 | 108,800 | D |
Explanation of responses
- F1The shares of common stock underlying this stock option award vest in equal quarterly installments over the four years after January 1, 2018.